Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q3 revenue rises 3.1% to $624.9 million; GAAP EPS falls 10.8%

Mixed Impact 3 of 5 earnings Written later

Chemed reported third-quarter 2025 results for the period ended September 30, 2025, with revenue up 3.1% to $624.9 million while GAAP diluted EPS fell 10.8% to $4.46 and adjusted diluted EPS fell 6.6% to $5.27. The company reiterated its 2025 adjusted diluted EPS guidance of $22.00 to $22.30 per share.

Key points

  • Revenue rose 3.1% to $624.9 million; VITAS net revenue rose 4.2% to $407.7 million and Roto-Rooter revenue rose 1.1% to $217.2 million.
  • GAAP diluted EPS was $4.46, down from $5.00 a year earlier; adjusted diluted EPS was $5.27, down 6.6%.
  • Consolidated Adjusted EBITDA was $109.0 million, compared with $123.0 million in the prior-year quarter, per the EBITDA reconciliation.
  • 2025 guidance of $22.00 to $22.30 per share was reiterated and assumes no Medicare Cap for the Florida combined program from October 1, 2025.

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECOct 28, 2025, 4:31 PM ET
Accession number0000019584-25-000004

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.